Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522556-10-01

Enrollment

Registered

2026-01-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Sequelae in Lyell syndrome

Brief summary

The primary efficacy endpoint of this study is the change in tear film break-up time (TBUT), measured in seconds, between baseline (Day 0) and post-treatment follow-up visits, Secondary efficacy endpoints will consist of patient-reported outcome measures designed to capture the subjective impact of treatment on ocular symptoms and vision-related quality of life.

Detailed description

Clinical Safety Monitoring, Patient-Reported Tolerability via DL-QI

Interventions

DRUGIlumetri 200 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary efficacy endpoint of this study is the change in tear film break-up time (TBUT), measured in seconds, between baseline (Day 0) and post-treatment follow-up visits, Secondary efficacy endpoints will consist of patient-reported outcome measures designed to capture the subjective impact of treatment on ocular symptoms and vision-related quality of life.	—

Secondary

Measure	Time frame
Clinical Safety Monitoring, Patient-Reported Tolerability via DL-QI	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026